Khondrion - Radboudumc

html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

Radboudumc and partners Spin-off companies Khondrion

About Khondrion

Khondrion is a pharmaceutical company focusing on the discovering and development of innovative drugs to treat Mitochondrial disease. read more

About Khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. The company is advancing its proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.

The company’s in-house discovery engine is using unique live-cell imaging technologies, patient-derived cell lines and predictive cell-based disease models to build a portfolio of promising compounds. Active discovery programmes are underway developing new therapies, biomarkers and new read-out technologies in the field of mitochondrial diseases.

To accelerate the discovery and development of its potential medicines for mitochondrial diseases, Khondrion collaborates with a global clinical and academic network and patient organisations internationally. Khondrion is headquartered in Nijmegen, The Netherlands.

Khondrion Details

CEO: Jan Smeitink
Affliated department: Pediatrics
Researcher: Jan Smeitink
Year of incorporation: 2007

Khondrion website

News

Sonlicromanol seems promising for certain cancers Khondrion announces publication in PLOS ONE of new research

13 July 2021 Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite.

Khondrion announced the dosing of first patient in their Khenergy study

7 May 2021 Our spin-off Khondrion announced the dosing of first patient in their Khenergy study to explore the pharmacokinetics, safety and efficacy of sonlicromanol in children with a genetically confirmed primary mitochondrial disease and suffering from motor symptoms

Medication for the body's malfunctioning energy system in the works

28 April 2021 Radboudumc’s spin-off company Khondrion is developing the promising drug sonlicromanol for treating energy metabolism diseases. Founder of the company Jan Smeitink, theme metabolic disorders, explains.

Khondrion begins study on optimal dosage of new drug

10 February 2020 Pharmaceutical company Khondrion, a spin-off from Radboudumc, has taken another important step in the development of its drug sonlicromanol. The first patients have used the drug as part of a phase 2b study, which focuses on determining the optimum dose and efficacy.

What we do

spin-off companies

Employees
mijnRadboud